Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,389,864
  • Shares Outstanding, K 46,546
  • Annual Sales, $ 674,980 K
  • Annual Income, $ 41,960 K
  • 60-Month Beta 0.77
  • Price/Sales 2.04
  • Price/Cash Flow 6.70
  • Price/Book 1.41
Trade PCRX with:

Options Overview Details

View History
  • Implied Volatility 37.15% ( -15.20%)
  • Historical Volatility 42.48%
  • IV Percentile 13%
  • IV Rank 28.34%
  • IV High 97.16% on 05/03/24
  • IV Low 13.41% on 09/20/23
  • Put/Call Vol Ratio 0.57
  • Today's Volume 451
  • Volume Avg (30-Day) 627
  • Put/Call OI Ratio 3.29
  • Today's Open Interest 16,719
  • Open Int (30-Day) 12,604

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.55
  • Number of Estimates 7
  • High Estimate 0.64
  • Low Estimate 0.50
  • Prior Year 0.61
  • Growth Rate Est. (year over year) -9.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.33 +16.15%
on 04/26/24
30.70 -4.17%
on 05/10/24
+1.59 (+5.71%)
since 04/10/24
3-Month
25.33 +16.15%
on 04/26/24
31.47 -6.51%
on 03/07/24
+0.64 (+2.22%)
since 02/09/24
52-Week
25.33 +16.15%
on 04/26/24
42.96 -31.52%
on 05/11/23
-13.47 (-31.41%)
since 05/10/23

Most Recent Stories

More News
Pacira: Q1 Earnings Snapshot

Pacira: Q1 Earnings Snapshot

PCRX : 29.42 (-1.47%)
Pacira: Q4 Earnings Snapshot

Pacira: Q4 Earnings Snapshot

PCRX : 29.42 (-1.47%)
Pacira: Q3 Earnings Snapshot

Pacira: Q3 Earnings Snapshot

PCRX : 29.42 (-1.47%)
Pacira: Q2 Earnings Snapshot

Pacira: Q2 Earnings Snapshot

PCRX : 29.42 (-1.47%)
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona

bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.

LGND : 87.28 (+1.35%)
PCRX : 29.42 (-1.47%)
BLUE : 1.0600 (-5.36%)
SPRO : 1.6400 (-2.96%)
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates

Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.

LGND : 87.28 (+1.35%)
PCRX : 29.42 (-1.47%)
SPRO : 1.6400 (-2.96%)
VTRS : 11.16 (-0.53%)
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat

Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices.

LGND : 87.28 (+1.35%)
PCRX : 29.42 (-1.47%)
FATE : 4.08 (+4.62%)
SPRO : 1.6400 (-2.96%)
Compared to Estimates, Pacira (PCRX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to...

PCRX : 29.42 (-1.47%)
Pacira (PCRX) Lags Q1 Earnings Estimates

Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PCRX : 29.42 (-1.47%)
COLL : 31.50 (-16.80%)
Pacira: Q1 Earnings Snapshot

Pacira: Q1 Earnings Snapshot

PCRX : 29.42 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 31.93
2nd Resistance Point 31.31
1st Resistance Point 30.37
Last Price 29.42
1st Support Level 28.81
2nd Support Level 28.19
3rd Support Level 27.25

See More

52-Week High 42.96
Fibonacci 61.8% 36.23
Fibonacci 50% 34.15
Fibonacci 38.2% 32.06
Last Price 29.42
52-Week Low 25.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar